Pre-made Afutuzumab benchmark antibody ( Whole mAb, anti-MS4A1/CD20 therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-013
Pre-Made Afutuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Obinutuzumab (called afutuzumab until 2009) is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Afutuzumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||3pp3:HL:IK/3pp4:HL|
|99% SI Structure||6y9a:HL|
|95-98% SI Structure||6y97:HL|
|Companies||GLYCART Biotechnology;Biogen Idec;Chugai Pharmaceutical;Dana-Farber Cancer Institute;Genentech;Lymphoma Academic Research Organisation;Nippon Shinyaku;OHSU Knight Cancer Institute;Pharmacyclics;Polish Myeloma Consortium;Roche;Thomas Jefferson University;University of Heidelberg;University of Leeds|
|Conditions Approved||Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma|
|Conditions Active||Diffuse large B cell lymphoma;CNS cancer;Graft-versus-host disease;Lupus nephritis;Mantle-cell lymphoma;Waldenstrom's macroglobulinaemia|
|Conditions Discontinued||Primary biliary cirrhosis|
|Development Tech||GlycoMAb Technology|